首页> 外文期刊>The Journal of dermatological treatment >Management strategies of autoimmune bullous diseases during the outbreak of 2019 Novel Coronavirus disease (COVID-19)
【24h】

Management strategies of autoimmune bullous diseases during the outbreak of 2019 Novel Coronavirus disease (COVID-19)

机译:2019年新型冠状病毒病(COVID-19)爆发期间自身免疫性大疱性疾病的管理策略

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Since late December 2019, an outbreak of the novel coronavirus disease, which is mainly characterized by pulmonary lesions, has spread quickly worldwide. With the spread of the novel coronavirus, the outpatient lines of hospitals have mostly shut down, which means that routine clinical diagnosis and treatment for autoimmune bullous diseases patients have been disturbed. Due to the serious condition of autoimmune bullous diseases patients, they are prone to immune suppression and circulatory failure, and are more susceptible to infection than healthy individuals. These patients should thus be a priority group for novel coronavirus disease prevention. In this context, the protection and control measures for autoimmune bullous diseases patients against the novel coronavirus are of serious concern. Clinicians should strengthen their communication with patients, pay attention to changes in patients' conditions, and carefully adjust the treatment strategy, while protecting against the novel coronavirus infection, to ensure the continuity, safety, and effectiveness of autoimmune bullous diseases treatment.
机译:自2019年12月下旬以来,以肺部病变为主要特征的新型冠状病毒病的爆发在世界范围内迅速蔓延。随着新型冠状病毒的传播,医院的门诊线路大多关闭,这意味着自身免疫性大疱性疾病患者的常规临床诊断和治疗受到干扰。由于自身免疫性大疱性疾病患者病情严重,容易出现免疫抑制和循环衰竭,比健康人更容易受到感染。因此,这些患者应成为预防新型冠状病毒病的优先群体。在此背景下,自身免疫性大疱性疾病患者对新型冠状病毒的防护和控制措施备受关注。临床医生应加强与患者的沟通,关注患者病情的变化,在预防新型冠状病毒感染的同时,确保自身免疫性大疱性疾病治疗的连续性、安全性和有效性。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号